| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000015646 |
| Receipt No. | R000018191 |
| Scientific Title | The safety and usability assessment of sunscreen agents (cosmetics) for light-sensitive patients |
| Date of disclosure of the study information | 2014/11/10 |
| Last modified on | 2019/03/31 (Ver. 10) |
| Basic information | ||
| Public title | The safety and usability assessment of sunscreen agents (cosmetics) for light-sensitive patients | |
| Acronym | The safety and usability assessment of sunscreen agents | |
| Scientific Title | The safety and usability assessment of sunscreen agents (cosmetics) for light-sensitive patients | |
| Scientific Title:Acronym | The safety and usability assessment of sunscreen agents | |
| Region |
|
|
| Condition | ||
| Condition | Light-sensitive patients including such as xeroderma pigmentosum, chronic actinic dermatitis, photosensitivity dermatitis, drug-induced photosensitivity | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Veridation of the safety(10% or less rate of adverse effect) and usability in light-sensitive patients by applying sunscreen agents to sun-exposure area of the light-sensitive patients for 4 weeks |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | the safety(10% or less rate of adverse effect |
| Key secondary outcomes | the usability(the changes of skin findings and cytokines in the stratum corneum)
|
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Applying sunscreen agents to sun-exposure area of light-sensitive patients for 4 weeks | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.Patients diagnosed with photosensitivity, who is determined that the use of this reserch article is useful therapeutically
2.Regardless of age or sex 3.Patients (whose legal representative in the case of minors) are in agreement In addition, we define photosensitivity as follows in this study. 1.photosensitivity disease including such as xeroderma pigmentosum, chronic actinic dermatitis, photosensitivity dermatitis,drug-induced photosensitivity 2.the diseases exacerbated by sun exposure including such as systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, dermatomyositis, rosacea-like dermatitis, Sjogren's syndrome 3.the diseases which is desirable to avoid sun exposure therapeutically for in improving disease, including atopic dermatitis, pigment spots (such as after laser treatment). |
|||
| Key exclusion criteria | 1.Those who have experience with the use of sunscreen agents, resulted in a skin severe symptoms in the past.
2.Those who have skin eruption on the application area of this research article. 3.The case that the interference of this reserch article and other topical product is expected. 4.Pregnant or nursing women 5.Those who can not (in principle) be examined after 4 weeks 6.Those who are deemed inappropriate to participate in this study by doctor. |
|||
| Target sample size | 140 | |||
| Research contact person | |||||||
| Last name of lead principal investigator |
|
||||||
| Organization | Kobe University Graduate School of Medicine(Kobe University Hospital) | ||||||
| Division name | Department of Dermatology, | ||||||
| Zip code | 650-0017 | ||||||
| Address | 7-5-2 Kusunoki-cho, Chuo-ku, | ||||||
| TEL | 078-382-6134 | ||||||
| dermatol@med.kobe-u.ac.jp | |||||||
| Public contact | |||||||
| 1st name of contact person |
|
||||||
| Organization | Kobe University Graduate School of Medicine(Kobe University Hospital) | ||||||
| Division name | Department of Dermatology | ||||||
| Zip code | 650-0017 | ||||||
| Address | 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Japan | ||||||
| TEL | 078-382-6134 | ||||||
| Homepage URL | |||||||
| atsushi@med.kobe-u.ac.jp | |||||||
| Sponsor | |
| Institute | Kobe University Graduate School of Medicine(Kobe University Hospital) |
| Institute | |
| Department | |
| Funding Source | |
| Organization | TOKIWA Pharmaceutical Co.,Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Kobe University Graduate School of Medicine(Kobe University Hospital)
Department of Dermatology, Hokkaido University Graduate School of Medicine(Hokkaido University Hospital) Graduate School of Medicine, Kyoto University(Kyoto University Hospital) Kyushu University, Graduate School of Medical Sciences(Kyushu University Hospital) Faculty of life science, Kumamoto University(Kumamoto University Hospital) Kanagawa Chirdren's Medicalcenter Rikako's Clinic of Dermatology |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | KOBE Univ. Hosp. CRB |
| Address | 7-5-2 kusunoki-cho chuo-ku Kobe Japan |
| Tel | 078-382-6669 |
| cerb@med.kobe-u.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 31 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018191 |